source
- Sanofi eyes 'moonshot' drug acquisitions to offset upcoming Dupixent patent lossSanofi's CFO Francois-Xavier Roger told Fierce that the company is looking at 'moonshot' treatments as potential acquisition targets to rebuild its pipeline. The push comes as the U.S. patent on D…
- Sanofi plans to pursue higher European drug prices rather than delay product launches under Trump policySanofi indicated it may seek higher drug prices in Europe as part of a deal related to President Trump's pricing policies. Unlike other major European pharma companies that have warned the policie…